

## CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number: 38

Manuscript word count: 9858

		Comments
Item No.	Specific items for verification	Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Clinical Oncology	
	Manuscript NO.: 66382	
	Column: Retrospective Study	
	Title: Pathological response to neoadjuvant therapy with	
	chemotherapy (Ch) versus Ch-radiotherapy in NSCLC stage III.	
	Contribution of IASLC recommendations.	
1	Authors: Diego Muñoz Guglielmetti, David Sanchez-Lorente,	[Y ]
1	Roxana Reyes, Daniel Martinez, Carmen Lucena, Marc Boada, Pilar	
	Paredes, Marta Parera-Roig, Ivan Vollmer, Joel Mases, Roberto	
	Martin-Deleon, Sergi Castillo, Mariana Benegas, Silvia Muñoz,	
	Maria Mayoral, Carla Cases, Meritxell Mollà and Francesc Casas	
	Reviewer code: 05227913	
	<b>First decision:</b> 2021-06-16 04:53	
	Scientific Editor: Man Liu	
	Date of signature: <u>10/21/2021</u> (month/day/year)	
	Editorial Office's Comments	
2	Science Editor: 1 Scientific quality: The manuscript describes a	[Y ]
	retrospective study of the pathological response to neoadjuvant	



# Baishideng Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

therapy in NSCLC stage III. The topic is within the scope of the WJCO. (1) Classification: Grade A; (2) Summary of the Peer-Review Report: This is a successful surgical result, and this study that will contribute to the literature. However, there are some issues need to be addressed. The authors need to add more details in the "method" section. The questions raised by the reviewers should be answered; and (3) Format: There are 6 tables. (4) References: A total of 40 references are cited, including 7 references published in the last 3 years; (5) Self-cited references: There are no self-cited references; and (6) References recommendations: The authors have the right to refuse to cite improper references recommended by the peer reviewer(s), especially references published by the peer reviewer(s) him/herself (themselves). If the authors find the peer reviewer(s) request for the authors to cite improper references published by him/herself (themselves), please send the peer reviewer's ID number to editorialoffice@wjgnet.com. The Editorial Office will close and remove the peer reviewer from the F6Publishing system immediately. 2 Language evaluation: Classification: Grade B. 3 Academic norms and rules: The authors provided the Biostatistics Review Certificate, and the Institutional Review Board Approval Form. The authors need to provide the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement, and informed consent. No academic misconduct was found in the Bing search. 4 Supplementary comments: This is an invited manuscript. The topic has not previously been published in



	the WJCO. The corresponding author has not published articles in	
	the BPG. 5 Issues raised: I found the authors did not write the	
	"article highlight" section. Please write the "article highlights"	
	section at the end of the main text. 6 Re-Review: Not required. 7	
	Recommendation: Conditionally accepted.	
	Company Editor-in-Chief: I have reviewed the Peer-Review	
	Report, full text of the manuscript, and the relevant ethics	
	documents, all of which have met the basic publishing requirements	
	of the World Journal of Clinical Oncology, and the manuscript is	
	conditionally accepted. I have sent the manuscript to the author(s)	
	for its revision according to the Peer-Review Report, Editorial	
	Office's comments and the Criteria for Manuscript Revision by	
	Authors.	
3	The fixed headings are copied.	[ Y]
	The title concisely summarizes the main topic of the study and is	
	not too long (no more than 18 words). Words such as 'exploration',	
4	'research', 'analysis', 'observation', and 'investigation' are avoided.	[ Y]
	The title does not start with 'The' and does not include any Arabic	
	numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[ Y]
	The authors' full family (sur)names and full/abbreviated first	
6	names are listed on the title page and are consistent with those	[ Y]
	listed in the signed BPG Copyright License Agreement form.	



7	The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names. <i>e.g.,</i> "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents and analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the manuscript. All authors have read and approve the final manuscript."	[ Y]
8	The 'Supported by' statement describes the source(s) of financial support and includes the corresponding identification number(s) and program ID(s) if available, and contains no spelling errors.	[N]
9	The 'Corresponding author' passage provides the corresponding author's full first and family (sur)names, abbreviated title ( <i>e.g.</i> , MD, PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors.	[Y]
10	The Manuscript Tracking information ( <i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.	[Y]
11	The Abstract section is formatted according to the article-specific style (structured <i>vs</i> unstructured) and word count thresholds, as follows: <u>Commentary, Frontier, Diagnostic Advances, Medical Ethics,</u> <u>Minireview, Review, Therapeutics Advances, and Topic Highlight</u> : Non-structured abstract that is no less than 200 words. <u>Field of Vision, Case Report and Letter to the Editor</u> :	[Y]



	Non-structured abstract that is no less than 150 words.	
	Research articles: Structured abstract with subsections for AIM (no	
	more than 20 words); METHODS (no less than 80 words); RESULTS	
	(no less than 120 words); and CONCLUSION (no more than 26	
	words).	
	The 'Key words' list provides 5-10 keywords that reflect the main	
12	content of the study. The first letter of each keyword is capitalized,	[Y]
	and each keyword is separated by a semicolon.	
	The "citation" contains authors' names and manuscript title. The	
	name of the first author should be typed in bold letters; the family	
	(sur) name of all authors should be typed with the first letter	
	capitalized, followed by their abbreviated first and middle initials.	
13	For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick	[ Y]
	Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,	
	Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes	
	mellitus increases the risk of gastric cancer: A meta-analysis. World J	
	<i>Gastroenterol</i> 2019; In press	
	The 'Core tip' provides a summary (less than 100 words) of the	
14	study that outlines the most innovative and important arguments	
14	and core contents of the paper and will serve to effectively attract	[ Y]
	readers.	
	The 'INTRODUCTION' section clearly describes the relevant	
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the	
15	exception of rare instances of seminal literature citations. All	
	technical terms and/or abbreviations are explained and/or defined,	[Y]
	with the full name of abbreviations given upon first appearance in	
	the text and the abbreviation presented in parentheses [i.e.,	
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I',	
	'we') are used appropriately to clearly indicate the work performed	



	by the author(s). When weaknesses of previous studies are	
	described in the text to highlight the innovations related to the	
	current study, the information is presented carefully.	
	The 'MATERIALS AND METHODS' section clearly and accurately	
10	describes all materials and methods used to obtain the data	
16	presented in the article and is adequate for a reader to repeat the	[Y]
	study.	
	The 'RESULTS' section concisely describes the observational and	
	experimental results. Representative data and data that have	
	scientific significance are emphasized. Data is presented in either	
17	the text, a table or figure ( <i>i.e.</i> , chart, diagram, graph or image), but is	[Y]
	not repeated among each. Information presented in the tables and	
	figures clearly describes the trends, meaning, and inferences.	
	Results described in textual form are accurate, concise and clear.	
	Statistical symbols are accurate. Statistical significance is expressed	
18	as ${}^{a}P < 0.05$ , ${}^{b}P < 0.01$ ( $P > 0.05$ usually does not need to be denoted).	
	If there are other series of <i>P</i> values, ${}^{c}P < 0.05$ and ${}^{d}P < 0.01$ are used,	[ Y ]
	and a third series of <i>P</i> values is expressed as ${}^{e}P < 0.05$ and ${}^{f}P < 0.01$ .	
	Statistical data is expressed as mean $\pm$ SD or mean $\pm$ SE.	
	survival and is expressed as mean 200 of mean 200.	



19	The 'DISCUSSION' section (1) describes the main purpose and	
	hypothesis of the study; (2) summarizes the most important results;	
	(3) illustrates and explains the results (but does not simply repeat	
	the data) and draws conclusions or inferences based on the results;	
	(4) points out the limitations of the study and their impact on the	[ Y]
	results, as well as proposes further advice on future research	
	topic(s) or direction(s); and (5) describes the theoretical significance	
	and practical value of the findings.	
	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any	
	individuals or organizations for technical support (i.e., providing	
	instrumentation, equipment or experimental materials, and/or	
20	assistance in experimental work), non-technical services ( <i>i.e.</i> , useful	[N]
	inspiration, suggestions, guidance, or review), and/or any other	
	auxiliary work.	
01	The 'ARTICLE HIGHLIGHTS' section provides comments for	
21	original articles in accordance with the specified format.	[Y]
	The 'REFERENCES' section lists the references in the Vancouver	
	style. This style uses Arabic numeral in-text citations based on the	
	order of the first appearance of a source in the text. For citations	
	where the author's name is indicated in the text, a superscript	
	number should be placed following the name ( <i>i.e,</i> "Pang <i>et al</i> "). For	
	citations where no author is indicated, a superscript number should	
22	be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup>	[Y]
	reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high	
	sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the	
	reference number is described in the text; for example, "The	
	experimental method used has been described in reference [8]." The	
	style of reference citations in tables is the same as that in the text	
	(e.g., Pan et $al^{[2-5]}$ , please see reference [8]).	
1	1	



22	Journal references have been verified to ensure that there are no	
	duplicate references and that the PMID numbers are correct. For	
	references not yet included in PubMed: the name of Chinese	
	journals is spelled out using Chinese Pinyin, with the first letter of	
23	each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of	[Y]
	journals in other languages are listed according to indexing	
	information retrieved from Google. Book references are presented	
	with all the information relevant to the electronic version.	
	The number of cited references is appropriate for the article type, as	
	follows:	
24	<u>Commentary:</u> no less than 50;	5 × 1
24	<u>Review:</u> no less than 100;	[ Y]
	<u>Article:</u> no less than 30/26;	
	Case Report and Letter to the Editor: no less than 1.	
	The ethics-related statements are provided in accordance with the	
25	manuscript type (e.g., Manuscript NoInstitutional review board	[ Y]
	statement, Manuscript NoAnimal care and use statement, etc.).	
	The names of the peer reviewers and the scientific editor are present	
26	at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang	[ Y]
	JL).	
	The order and numerical labeling of tables and figures is consistent	
	with their appearance and presentation in the text. Symbols in	
	tables ( <i>e.g.</i> , +, -, ×, $\div$ , *) correctly correspond to the definitions in the	
27	footnotes. Only one legend is provided for each multi-panel figure	[ N1]
27	consisting of color graphs, black and white graphs, or line graphs	[ N]
	that depicts data of the same theme. For example: Figure 1	
	Pathological changes in atrophic gastritis tissue before and after	
	treatment. A:; B:; C:; D:; E:; F:	
28	Split pictures include flow charts, line graphs, histograms, and	[Y]
20	graphs including text. Unsplit pictures include meta-analysis	



	diagrams, PCR amplification curves, and survival curves.	
29	The author(s) highlighted the changes made to the manuscript	[Y]
	according to the peer-reviewers' comments.	
30	The responses to the peer-reviewers' comments are consistent with	[Y]
	the changes made to the manuscript.	[ - ]
	The revised manuscript is provided (file name: Manuscript	
	NoReview; <i>e.g.</i> , 870- Review).	
21	The letter of peer-reviewers' comments is provided (file name:	
31	Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).	[ Y]
	The response letter is provided (file name: Manuscript	
	NoAnswering reviewers; e.g., 870-Answering reviewers).	
	The related ethics and relevant documents are provided, such as (1)	
	Approved grant application form(s) or funding agency copy of any	
	approval document(s) (file name: Manuscript NoGrant application	
	form(s)); (2) Biostatistics review certificate (file name: Manuscript	
	NoBiostatistics statement); (3) Conflict-of-interest statement (file	
	name: Manuscript NoConflict-of-interest statement); (4) Clinical	
	trial registration statement (file name: Manuscript NoClinical trial	
32	registration statement); (5) Institutional review board approval form	[Y]
	or document (file name: Manuscript NoInstitutional review board	
	statement); (6) Institutional animal care and use committee	
	approval form or document (file name: Manuscript	
	NoInstitutional animal care and use committee statement), and (7)	
	Signed informed consent form(s) or document(s) (file name:	
	Manuscript NoInformed consent statement).	
33	All authors signed the BPG Copyright license agreement form (file	
	name: Manuscript NoCopyright license agreement; <i>e.g.</i> ,	[Y]
	870-Copyright license agreement).	
	The language certificate provided by authors who are non-native	
34		[ Y]
	speakers of English meets the BPG requirements (file name:	



	Manuscript NoLanguage certificate; e.g., 870-Language certificate).	
35	The photos licensed in the Agreement for Use of Personal Photos	
	are consistent with those in the paper (file name: Manuscript	[ N]
	NoAgreement for use of personal photos; e.g., 870-Agreement for	[]
	use of personal photos).	
	This document (Checklist of Responsibilities for Scientific Editors)	
36	has been saved under the file name: manuscript NoScientific	[Y]
	editor work list (e.g., 870-Scientific editor work list).	
	A CrossCheck investigation (an effective tool for detecting unoriginal	
	content, enabling our editors to preserve the journal's integrity and	
	the authors' copyright) has been performed for the manuscript via	
	the website: http://www.ithenticate.com/. The results document	
37	contains the following information for the manuscript: "Name of	
	journal", "Manuscript No.", "Columns", "Title" and "Author list".	[Y ]
	The Figure of the CrossCheck results is saved in JPEG format (.jpg) at	
	1440 × 680 pixel resolution. The PDF of the CrossCheck results has	
	been saved under the file name: manuscript No CrossCheck report	
	(e.g., 870-CrossCheck report). The Google searches have also been	
	performed to further ensure publication of original content.	
20	The text of the manuscript is typed in Book Antiqua font, 12 pt, with	
38	1.5 line spacing.	[ Y]
	The primary responsibilities of our scientific editors include carefull	y checking the
	entire manuscript and all accompanying materials for: (1) error	rs in spelling.
Responsibilities		1 0
of scientific editors	grammar, punctuation and wording; (2) suitability of tables, figures, f	-
	legends; (3) accurate and appropriate presentation of symbols ( <i>e.g.</i> +,	-, ×, ÷, %, *) in
	tables and figures; and (4) complete and comprehensive revision of t	the manuscript
	according to the reviewers' comments.	
	1	



	Manuscript reception and registration $\rightarrow$ Initial review by scientific editor $\rightarrow$ Peer	
	$review \rightarrow End  of  peer  review \rightarrow First  round  of  meeting  evaluation \rightarrow To  be$	
	accepted $\rightarrow$ Revision by the author(s) $\rightarrow$ Second round of meeting evaluation $\rightarrow$ To be	
	accepted/revised/rejected $\rightarrow$ Final review by the Editor-in-Chief (final quality	
Publication	control for academic content and language quality) $\rightarrow$ Final acceptance and charging	
process	of publication fee $\rightarrow$ Language editing $\rightarrow$ Production $\rightarrow$ Proofreading by scientific	
	$editor {\rightarrow} Proof reading \ by \ deputy \ editor {\rightarrow} Final \ review \ by \ Editor {-} in - Chief {\rightarrow} Release$	
	of online open-access papers in electronic form on the BPG website $\rightarrow$ Release of	
	online papers on PubMed Central→Delivery of high-quality PDF reprints to the	
	author(s) $\rightarrow$ End of the publication process.	